Loading
NFL Biosciences Stock: price and insider trades · France
NFL Biosciences: what insiders have been doing
Every trade that managers of NFL Biosciences disclose to AMF is tracked on this page. The company sits in the Healthcare & Pharma sector. NFL Biosciences has had no insider filing for more than a year; the last one goes back to 8 September 2025.
Since 2023, the database holds no purchases and 5 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from AMF disclosures alone and does not predict where the share price will go.
Insider Decl.
9
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€353,635
5 ops. · all time
Who traded when
BuySaleBruno Lafont2 sales
Financial data
as of FY 2025FY ended December 2025 · cache
€0.62
Analyst consensus
Income statement
Gross profit-€2.5M
EBITDA-€3.8M
Net income-€3.3M0.0% margin
Valuation
P/Book25.8x
Beta1.28
Balance sheet & cash
Market cap€7.9M
Total debt€583k
Debt / Equity190%
Profitability & ownership
ROE-517.4%
ROA-66.6%
% insiders14.2%
% institutions0.0%
Last declaration on 8 September 2025
Declarations9 total
18,000 shares@ €1.52255.9% of flowActionEuronext Growth ParisISIN FR0014003XT02025DD1056681
41,650 shares@ €1.188210.7% of flowActionEuronext Growth ParisISIN FR0014003XT02025DD1049758
250,000 shares@ €0.3016.2% of flowActionEuronext Growth ParisISIN FR0014003XT02025DD1032010
6,568 shares@ €2.5814100.0% of flowActionEuronext Growth ParisISIN FR0014003XT02023DD920561
500,000 shares@ €0.1010.8% of flowActionEuronext Growth ParisISIN FR0014003XT02023DD918253
57,000 shares@ €2.653932.8% of flowActionEuronext Growth ParisISIN FR0014003XT02023DD918168
43,000 shares@ €2.523623.5% of flowActionEuronext Growth ParisISIN FR0014003XT02023DD918207
71,778 shares0ActionEuronext Growth ParisISIN FR0014003XT02023DD897035
71,778 shares0ActionEuronext Growth ParisISIN FR0014003XT02023DD896929
9 of 9 declarations
About NFL Biosciences
NFL BIOSCIENCES is a French biopharmaceutical company listed on Euronext Growth Paris under ISIN FR0014003XT0 and ticker ALNFL. Headquartered in Castelnau-le-Lez, near Montpellier, the company develops innovative botanical medicines for the treatment of addictions, with a long-standing focus on smoking cessation. Its model is that of a specialty biotech centered on plant-derived drug candidates, designed to be licensed to pharmaceutical partners rather than widely marketed directly by the company. This partnership-led strategy allows NFL BIOSCIENCES to concentrate on research, clinical validation and intellectual property value creation. The company was co-founded in 2009 by Bruno Lafont, who now serves as Chairman of the Board and CEO, with the ambition of turning botanical extracts into standardized, reproducible therapies that can meet strict regulatory requirements.
Its pipeline is built around several programs. NFL-101 is the most advanced candidate; it is a standardized tobacco-leaf extract developed to help smokers quit. NFL-102 is another smoking-cessation candidate aimed at a broader population, while NFL-301 is focused on excessive alcohol consumption and is based on kudzu extract. The company emphasizes a scientific approach rooted in the biology of addiction, aiming to go beyond symptom relief and address the underlying neurobiological mechanisms that drive dependence and relapse.
Read moreShow less
NFL BIOSCIENCES also stands out for its structured intellectual-property portfolio, which includes multiple patent families, and for its lean operating model with outsourced research and controlled fixed costs. Manufacturing is carried out in France in compliance with Good Manufacturing Practices, reinforcing the industrial credibility of the platform. In 2025 and early 2026, the company continued to advance its clinical and regulatory programs while securing additional funding from long-standing supporters such as Bpifrance. Following an April 2026 bond financing, its cash runway was extended to the third quarter of 2027, an important visibility factor for a pre-commercial biotech. Overall, NFL BIOSCIENCES is positioned as a niche French biotechnology company with exposure to the addiction-treatment market and a value-creation strategy centered on licensing.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
